Primary Resistance to Afatinib in a Patient with Lung Adenocarcinoma Harboring Uncommon EGFR Mutations: S768I and V769L

被引：7

作者：

Niogret, Julie ^{[1
]}

Coudert, Bruno ^{[1
]}

Boidot, Romain ^{[2
,3
]}

机构：

[1] Georges Francois Leclerc Canc Ctr UNICANC, Dept Med Oncol, Dijon, France

[2] Georges Francois Leclerc Canc Ctr UNICANC, Platform Transfer Canc Biol, 1 Rue Prof Marion, F-21000 Dijon, France

[3] Georges Francois Leclerc Canc Ctr UNICANC, GIMI Genet & Immunol Med Inst, Dijon, France

来源：

JOURNAL OF THORACIC ONCOLOGY | 2018年 / 13卷 / 07期

关键词：

CANCER;

D O I：

10.1016/j.jtho.2018.02.004

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

引用

页码：E113 / E113

页数：1

共 5 条

[1] Non-responsiveness to gefitinib in a patient with lung adenocarcinoma having rare EGFR mutations S7681 and V769L [J].

Asahina, Hajime ;

Yamazaki, Koichi ;

Kinoshita, Ichiro ;

Yokouchi, Hiroshi ;

Dosaka-Akita, Hirotoshi ;

Nishimura, Masaharu .

LUNG CANCER, 2006, 54 (03) :419-422

[2] Molecular pathology of lung cancer: key to personalized medicine [J].

Cheng, Liang ;

Alexander, Riley E. ;

MacLennan, Gregory T. ;

Cummings, Oscar W. ;

Montironi, Rodolfo ;

Lopez-Beltran, Antonio ;

Cramer, Harvey M. ;

Davidson, Darrell D. ;

Zhang, Shaobo .

MODERN PATHOLOGY, 2012, 25 (03) :347-369

[3] S7681 Mutation Mutation in EGFR in Patients with Lung Cancer [J].

Leventakos, Konstantinos ;

Kipp, Benjamin R. ;

Rumilla, Kandelaria M. ;

Winters, Jennifer L. ;

Yi, Eunhee S. ;

Mansfield, Aaron S. .

JOURNAL OF THORACIC ONCOLOGY, 2016, 11 (10) :1798-1801

[4] Clinical activity of afatinib in patients with advanced non-small-cell lung cancer harbouring uncommon EGFR mutations: a combined post-hoc analysis of LUX-Lung 2, LUX-Lung 3, and LUX-Lung 6 [J].

Yang, James C-H ;

Sequist, Lecia V. ;

Geater, Sarayut Lucien ;

Tsai, Chun-Ming ;

Mok, Tony Shu Kam ;

Schuler, Martin ;

Yamamoto, Nobuyuki ;

Yu, Chong-Jen ;

Ou, Sai-Hong I. ;

Zhou, Caicun ;

Massey, Daniel ;

Zazulina, Victoria ;

Wu, Yi-Long .

LANCET ONCOLOGY, 2015, 16 (07) :830-838

[5] Afatinib versus cisplatin-based chemotherapy for EGFR mutation-positive lung adenocarcinoma (LUX-Lung 3 and LUX-Lung 6): analysis of overall survival data from two randomised, phase 3 trials [J].

Yang, James Chih-Hsin ;

Wu, Yi-Long ;

Schuler, Martin ;

Sebastian, Martin ;

Popat, Sanjay ;

Yamamoto, Nobuyuki ;

Zhou, Caicun ;

Hu, Cheng-Ping ;

O'Byrne, Kenneth ;

Feng, Jifeng ;

Lu, Shun ;

Huang, Yunchao ;

Geater, Sarayut L. ;

Lee, Kye Young ;

Tsai, Chun-Ming ;

Gorbunova, Vera ;

Hirsh, Vera ;

Bennouna, Jaafar ;

Orlov, Sergey ;

Mok, Tony ;

Boyer, Michael ;

Su, Wu-Chou ;

Lee, Ki Hyeong ;

Kato, Terufumi ;

Massey, Dan ;

Shahidi, Mehdi ;

Zazulina, Victoria ;

Sequist, Lecia V. .

LANCET ONCOLOGY, 2015, 16 (02) :141-151

← 1 →